Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Symeonidis

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemiaM A Dimopoulos, G Hamilos, K Zervas, et al.
Blood Cancer Journal|February 18, 2017
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromesP Diamantopoulos, K Zervakis, P Zervakis, et al.
International Journal of Cardiology|March 10, 2009
Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia studyA I Hatzitolios, V G Athyros, A Karagiannis, et al.
Leukemia|February 20, 2009
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)E Kastritis, K Zervas, A Symeonidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agentsM A Dimopoulos, S Delimpasi, E Katodritou, et al.
Annals of Hematology|April 27, 2002
Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of responseN Viniou, E Terpos, A Galanopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myelomaM A Dimopoulos, A Pouli, K Zervas, et al.
Leukemia|March 19, 2014
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myelomaE Kastritis, F Zagouri, A Symeonidis, et al.
Journal of Internal Medicine|December 8, 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndromeH K G Garelius, W T Johnston, A G Smith, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemiaM A Dimopoulos, G Hamilos, K Zervas, et al.
Blood Cancer Journal|February 18, 2017
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromesP Diamantopoulos, K Zervakis, P Zervakis, et al.
International Journal of Cardiology|March 10, 2009
Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia studyA I Hatzitolios, V G Athyros, A Karagiannis, et al.
Leukemia|February 20, 2009
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)E Kastritis, K Zervas, A Symeonidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agentsM A Dimopoulos, S Delimpasi, E Katodritou, et al.
Annals of Hematology|April 27, 2002
Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of responseN Viniou, E Terpos, A Galanopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myelomaM A Dimopoulos, A Pouli, K Zervas, et al.
Leukemia|March 19, 2014
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myelomaE Kastritis, F Zagouri, A Symeonidis, et al.
Journal of Internal Medicine|December 8, 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndromeH K G Garelius, W T Johnston, A G Smith, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Pageof 5